2nd International Pulmonary Hypertension / Heart Failure Symposium

Focus on Structural Heart Disease, Right Ventricular Dysfunction and Stem Cell Therapy


June 11 – 12, 2022 (1.5 day meeting)
Berlin, Germany

Hosted by The European Pediatric Pulmonary Vascular Disease Network
Venue: GLS Campus Berlin, Kastanienallee 82

Conference Chairs and Scientific Organizers:
Georg Hansmann and Martin Köstenberger

Endorsed by:
Register now!

Welcome to Berlin!

We cordially invite you to participate in the 2nd international, interdisciplinary “Pulmonary Hypertension/ Heart Failure Symposium” with focus on structural heart disease, right ventricular dysfunction and stem cell therapy.

The science presented at this symposium is not pediatric-specific.

A strength of this meeting is its multidisciplinary nature – bringing together basic-translational scientists and clinicians (cardiologists, pulmonologists, neonatologists, cardiothoracic surgeons, intensivists). In six different sessions spread over 1.5 days, this meeting will update you on recent discoveries and innovations, and addresses several important paradigm shifts in the field of pulmonary hypertension and heart failure:

  • Pulmonary vascular disease (PVD) relates in large part to increased cell proliferation, metabolic dysfunction, resistance to apoptosis, and inflammation (rather than vasoconstriction) – „cancer hypothesis“.

  • Stem cells, progenitor and differentiated blood cells play important roles in development of PVD and pulmonary arterial hypertension (PAH). Several pre-clinical studies have been reported the efficacy of stem cell therapy for PVD and heart failure, and the first phase Ia/b and II studies are underway.

  • Performance of the right ventricle, and its interaction with the left ventricle, is the key determinant of prognosis in PAH. Thus, innovative, non-invasive imaging of the hypertensive RV-PA unit, and the search for direct RV treatment targets, are paramount.

  • A dedicated session on Structural Heart Disease will deal with Diagnostics and Therapeutic Interventions on the RV-PA Unit and Single Ventricles.

  • Clinical trials and new trial designs related to pulmonary hypertension, ARDS, HFpEF/CpcPH and structural heart disease will be highlighted throughout this meeting.

Histology of advanced PVD

Pulmonary vascular disease (PVD) is characterized by progressive obliteration of pulmonary arterioles leading to increased pulmonary vascular resistance (PVR), pulmonary arterial hypertension (PAH), right heart failure, and death in ≈25-60% of patients 5 years after diagnosis. The pathobiology of PAH is complex and multifactorial, and none of the current therapies has been shown to be universally effective or able to reverse advanced pulmonary vascular disease, characterized by plexiform vascular lesions (image).

08:30 – 12:30h  |  Saturday, June 11, 2022 | Morning Program

*confirmed speakers, chairs and panelists

  • 07:45 – 08:30h  |  Registration

  • 08:30 – 10:30h  |  Session #1

Topic: Angiogenesis and Vascular Remodeling

Chairs/Panelists: George Caputa, Wolfgang Kübler*, Grazyna Kwapiszewska, Håkan Wåhlander

  • 8:30h Welcome – Georg Hansman
  • 8:35h: Keynote lecture #1 (20min.+5min) – TBA
  • 9:00h: Invited Talk (15min+5min) – Petra Knaus*, Berlin. Endothelial homeostasis and TGFbeta superfamily receptors in PAH
  • 9:20h: Invited Talk (15min+5min) – Bradley M. Maron*, Boston. Platelet-endothelial adhesion in the pulmonary circulation
  • 9:40h: Invited Talk (15min+5min) – TBA
  • 10:00h: Oral Abstract (10min+5min) – Karin Tran-Lundmark*, Lund. X-ray phase contrast imaging of pulmonary vascular disease
  • 10:15h: Oral Abstract (10min+5min) – Stine Andersen*, Aarhus. PA-banding models of RV failure
  • 10:30 – 11:00h  | Break & Industry Exhibition

Poster Set Up (# 1-10)

  • 11:00 – 12:30h  |  Session #2

Topic: Modern Imaging of Pulmonary Vascular Disease and Cardiac Dysfunction

Chairs/Panelists: Martin Koestenberger*, Guido Pieles, Joe Wu

  • 11:00h: Invited Talk (15min+5min) – TBA. Advanced echocardiography in pediatric pulmonary hypertension.
  • 11:20h: Invited Talk (15min+5min) – Eike Nagel, Frankfurt – Validation of CMR against invasive hemod